|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 13th Street NW |
Address2 | 11th Floor North |
City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400693064-63
|
||||||||
|
6. House ID# 415240005
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Melanie Nathanson |
Date | 1/12/2017 4:33:01 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues, policies focused on antibiotic resistance and other public health related policies.
S. 1549 - The Care Planning Act - supporting advances in End-of-Life Care throughout the nation.
S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction.
S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public.
S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program.
H.R. 5054 - Agriculture Appropriations Bill for FY 2017 - Issues related to FDA treatment of antibiotics and compounding of certain pharmaceuticals.
Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC.
Exploring new policies to improve end of life care in America.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues, policies focused on antibiotic resistance and other public health related policies.
S. 1549 - The Care Planning Act - supporting advances in End-of-Life Care throughout the nation.
S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction.
S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program.
Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC.
Exploring new policies to improve end of life care in America.
Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid.
Supporting policies to maintain the integrity of laws regarding compounding of certain medications.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues, policies focused on antibiotic resistance and other public health related policies.
S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction.
S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public.
S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program.
H.R. 5054 - Agriculture Appropriations Bill for FY 2017 - Issues related to FDA treatment of antibiotics and compounding of certain pharmaceuticals.
Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC.
Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget.
Supporting policies to maintain the integrity of laws regarding compounding of certain medications.
Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |